Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SARS1 | P49591 | 1/20 | 0.80 |
| ▸ | LARS1 | Q9P2J5 | 2/20 | 0.76 |
| ▸ | HARS1 | P12081 | 1/20 | 0.74 |
| ▸ | TARS1 | P26639 | 2/20 | 0.74 |
| ▸ | MARS1 | P56192 | 1/20 | 0.73 |
| ▸ | IARS1 | P41252 | 1/20 | 0.71 |
| ▸ | RARS1 | P54136 | 1/20 | 0.70 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phesa SCHEMBL3499221 | 1.00 | SARS1 (0.80) | SARS1LARS1HARS1TARS1MARS1 | |
| SCHEMBL4321355 | 0.93 | SARS1 (0.79) | SARS1LARS1HARS1TARS1MARS1 | |
| SCHEMBL30270578 | 0.89 | SARS1 (0.85) | SARS1LARS1HARS1TARS1MARS1 | |
| SCHEMBL21068060 | 0.89 | SARS1 (0.87) | SARS1LARS1HARS1TARS1MARS1 | |
| SCHEMBL3187665 | 0.89 | SARS1 (0.87) | SARS1LARS1HARS1TARS1MARS1 | |
| SCHEMBL3187637 | 0.89 | SARS1 (0.87) | SARS1LARS1HARS1TARS1MARS1 | |
| SCHEMBL4313369 | 0.89 | SARS1 (1.00) | SARS1LARS1HARS1TARS1MARS1 | |
| SCHEMBL21067959 | 0.89 | SARS1 (1.00) | SARS1LARS1HARS1TARS1MARS1 | |
| SCHEMBL3500697 | 0.88 | SARS1 (0.82) | SARS1LARS1HARS1TARS1MARS1 | |
| SCHEMBL178823 | 0.87 | SARS1 (0.85) | SARS1LARS1HARS1TARS1MARS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-121232272-A | Slope instability judging method based on energy spectrum amplitude under seismic power effect | 昆明理工大学 | 2025-12-30 | — | — | CN | disclosed |
| US-20250093263-A1 | FRET-BASED ASSAYS | THE GENERAL HOSPITAL CORPORATION | 2025-03-20 | — | — | US | disclosed |
| EP-4374157-A2 | FRET-BASED ASSAYS | The General Hospital Corporation (US) | 2024-05-29 | — | — | EP | disclosed |
| WO-2023004438-A2 | FRET-BASED ASSAYS | THE GENERAL HOSPITAL CORPORATION (US) | 2023-01-26 | — | — | WO | disclosed |
| US-8778631-B2 | Mono charging system for selectively introducing non-native amino acids into proteins using an in vitro protein synthesis system | SUTRO BIOPHARMA, INC. (US) | 2014-07-15 | — | — | US | disclosed |
| EP-2376647-B1 | MONO CHARGING SYSTEM FOR SELECTIVELY INTRODUCING NON-NATIVE AMINO ACIDS INTO PROTEINS USING AN IN VITRO PROTEIN SYNTHESIS SYSTEM | SUTRO BIOPHARMA INC (US) | 2014-03-05 | — | — | EP | disclosed |
| US-20100184135-A1 | MONO CHARGING SYSTEM FOR SELECTIVELY INTRODUCING NON-NATIVE AMINO ACIDS INTO PROTEINS USING AN IN VITRO PROTEIN SYNTHESIS SYSTEM | SUTRO BIOPHARMA, INC. (US) | 2010-07-22 | — | — | US | disclosed |
| US-20100184134-A1 | DUAL CHARGING SYSTEM FOR SELECTIVELY INTRODUCING NON-NATIVE AMINO ACIDS INTO PROTEINS USING AN IN VITRO SYNTHESIS METHOD | SUTRO BIOPHARMA, INC. (US) | 2010-07-22 | — | — | US | disclosed |
| US-20100133117-A1 | METHODS FOR ELECTROCHEMICAL DETECTION/QUANTIFICATION OF A NUCLEIC ACID | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2010-06-03 | — | — | US | disclosed |
| WO-2008097190-A1 | METHODS OF ELECTRICALLY DETECTING A NUCLEIC ACID BY MEANS OF AN ELECTRODE PAIR | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2008-08-14 | — | — | WO | disclosed |
| WO-2008018833-A1 | METHODS FOR ELECTROCHEMICAL DETECTION/QUANTIFICATION OF A NUCLEIC ACID | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2008-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250093263-A1 | FRET-BASED ASSAYS | TARBP1, GTPBP4, TERF2IP | SARS1 12/4885LARS1 86/4885HARS1 360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.